Only Loestrin Market Matters In Antitrust Row, Retailers Say

By Dani Kass (October 26, 2018, 7:28 PM EDT) -- Warner Chilcott can't avoid antitrust litigation over sales of its birth control medication Loestrin 24 by claiming it shares the market with all available oral birth control, as the allegations in the suit are much narrower and focus on generic competition, retailers told a Rhode Island federal court in a filing made public Friday....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!